December 4, 2009- Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called “Twist” may be the proverbial red flag that can accurately distinguish stem cells that drive aggressive, metastatic breast cancer from other breast cancer cells.
Building on recent work suggesting that it is a relatively rare subgroup of stem cells in breast tumors that drives breast cancer, scientists have surmised that this subgroup of cells must have some very distinctive qualities and characteristics.
Image by hoodiefanatic via Flickr
The key to eradicating tumors and preventing relapses and metastasis is buried within the tumor itself. The tumor cells themselves contain a sort of needle in the haystack. Just 1% of the total volume of the tumor is responsible for reproduction, and a targeted surgery or drugs could be sufficient enough to “deactivate” the tumor and avoid any possibility of a reoccurrence. This type of treatment could possibly change the therapeutic approach to malignant tumors according to an Italian study at the Superior Health Institute (ISS) by Professor Ruggero De Maria, the Director
What are the biological processes that stem cells go through? What are the industrial processes we need to manufacturing? What do we know about cancer stem cells? How do iPS cells fit into the picture vs. embryonic stem cells? In this episode we investigate how the science and research of stem cells is being translated into industrial cell processes to create FDA approvable, and commercializable products. Differentiation, proliferation, migration, retro-differentiation, trans-differentiation, transformation into cancer cells, the role of tumors‘ micro environments and epigenetics and all reviewed here by the field’s foremost experts.
Incoming search terms:biological concepts and processes relating